Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Opioid, delta | 7 | 2020 | 37 | 3.420 |
Why?
|
| Retinal Ganglion Cells | 7 | 2020 | 72 | 2.730 |
Why?
|
| Glaucoma | 4 | 2020 | 50 | 2.370 |
Why?
|
| Retina | 7 | 2021 | 252 | 1.720 |
Why?
|
| Optic Disk | 6 | 2020 | 37 | 1.630 |
Why?
|
| Receptors, Opioid | 5 | 2015 | 60 | 1.570 |
Why?
|
| Histone Deacetylases | 3 | 2020 | 99 | 1.450 |
Why?
|
| Benzamides | 5 | 2020 | 156 | 1.420 |
Why?
|
| Astrocytes | 6 | 2020 | 270 | 1.390 |
Why?
|
| Piperazines | 5 | 2020 | 206 | 1.390 |
Why?
|
| Blotting, Western | 14 | 2020 | 954 | 1.250 |
Why?
|
| Retinal Diseases | 3 | 2017 | 40 | 1.050 |
Why?
|
| Ocular Hypertension | 4 | 2014 | 43 | 1.020 |
Why?
|
| Electroretinography | 9 | 2021 | 122 | 0.980 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2013 | 626 | 0.970 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2013 | 145 | 0.960 |
Why?
|
| Eye | 4 | 2015 | 89 | 0.950 |
Why?
|
| Ciliary Body | 5 | 2013 | 52 | 0.930 |
Why?
|
| Muscle, Smooth | 4 | 2013 | 117 | 0.860 |
Why?
|
| Intraocular Pressure | 7 | 2020 | 143 | 0.850 |
Why?
|
| Uveitis | 1 | 2022 | 13 | 0.850 |
Why?
|
| Rats, Inbred BN | 9 | 2020 | 51 | 0.840 |
Why?
|
| Morphine | 3 | 2012 | 76 | 0.820 |
Why?
|
| Analgesics, Opioid | 4 | 2018 | 498 | 0.810 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 102 | 0.780 |
Why?
|
| Neuroprotective Agents | 3 | 2013 | 317 | 0.700 |
Why?
|
| Rats | 14 | 2020 | 5300 | 0.700 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2016 | 135 | 0.700 |
Why?
|
| Retinal Degeneration | 2 | 2012 | 75 | 0.680 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 163 | 0.660 |
Why?
|
| Reperfusion Injury | 3 | 2011 | 320 | 0.650 |
Why?
|
| Animals | 28 | 2021 | 20881 | 0.630 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 2550 | 0.630 |
Why?
|
| Dinoprost | 3 | 2008 | 27 | 0.620 |
Why?
|
| Optic Nerve Injuries | 1 | 2018 | 5 | 0.610 |
Why?
|
| Neuroprotection | 1 | 2017 | 28 | 0.590 |
Why?
|
| Cells, Cultured | 12 | 2020 | 2673 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 331 | 0.520 |
Why?
|
| Immunohistochemistry | 7 | 2017 | 1174 | 0.510 |
Why?
|
| Trabecular Meshwork | 2 | 2006 | 22 | 0.510 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 150 | 0.510 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 147 | 0.510 |
Why?
|
| Nitric Oxide | 3 | 2014 | 382 | 0.500 |
Why?
|
| Monophenol Monooxygenase | 1 | 2014 | 8 | 0.470 |
Why?
|
| Interferon-gamma | 2 | 2016 | 241 | 0.460 |
Why?
|
| Prostaglandins F, Synthetic | 3 | 2008 | 8 | 0.430 |
Why?
|
| Optic Nerve | 3 | 2017 | 55 | 0.370 |
Why?
|
| Ischemia | 1 | 2012 | 229 | 0.360 |
Why?
|
| Antihypertensive Agents | 3 | 2014 | 498 | 0.360 |
Why?
|
| Penile Erection | 2 | 2007 | 18 | 0.350 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2016 | 132 | 0.330 |
Why?
|
| Ischemic Preconditioning | 1 | 2009 | 31 | 0.330 |
Why?
|
| Narcotics | 1 | 2009 | 65 | 0.320 |
Why?
|
| Retinal Vessels | 1 | 2009 | 74 | 0.320 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2008 | 28 | 0.310 |
Why?
|
| Eye Diseases | 1 | 2008 | 38 | 0.310 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2022 | 126 | 0.300 |
Why?
|
| Protein Kinase C | 2 | 2006 | 270 | 0.290 |
Why?
|
| Impotence, Vasculogenic | 1 | 2007 | 2 | 0.290 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 95 | 0.290 |
Why?
|
| Male | 16 | 2020 | 37321 | 0.280 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2006 | 8 | 0.280 |
Why?
|
| Type C Phospholipases | 2 | 2006 | 67 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2004 | 250 | 0.260 |
Why?
|
| Chronic Disease | 3 | 2017 | 1330 | 0.260 |
Why?
|
| Isoenzymes | 2 | 2008 | 308 | 0.260 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2007 | 195 | 0.240 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 191 | 0.240 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 597 | 0.240 |
Why?
|
| Receptor, Bradykinin B2 | 3 | 2014 | 75 | 0.240 |
Why?
|
| Female | 12 | 2020 | 38074 | 0.230 |
Why?
|
| Humans | 19 | 2022 | 68618 | 0.230 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2004 | 10 | 0.230 |
Why?
|
| Signal Transduction | 5 | 2019 | 2689 | 0.230 |
Why?
|
| Calcium | 3 | 2008 | 929 | 0.230 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 266 | 0.220 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 134 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 6 | 2019 | 2791 | 0.210 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2002 | 19 | 0.200 |
Why?
|
| Acetylation | 2 | 2020 | 94 | 0.200 |
Why?
|
| Arachidonic Acids | 1 | 2002 | 97 | 0.200 |
Why?
|
| Enzyme Inhibitors | 3 | 2013 | 659 | 0.200 |
Why?
|
| Disease Progression | 2 | 2017 | 1038 | 0.200 |
Why?
|
| Analysis of Variance | 2 | 2014 | 1040 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 507 | 0.190 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 199 | 0.190 |
Why?
|
| Photoreceptor Cells | 1 | 2021 | 62 | 0.190 |
Why?
|
| Mice | 6 | 2021 | 8474 | 0.180 |
Why?
|
| Rhodopsin | 1 | 2021 | 135 | 0.180 |
Why?
|
| Cadaver | 1 | 2020 | 136 | 0.180 |
Why?
|
| Naloxone | 2 | 2011 | 56 | 0.180 |
Why?
|
| Eye Proteins | 1 | 2021 | 160 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 209 | 0.180 |
Why?
|
| Cell Survival | 2 | 2013 | 901 | 0.170 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 22 | 0.170 |
Why?
|
| Ligands | 2 | 2012 | 317 | 0.160 |
Why?
|
| PPAR gamma | 1 | 2019 | 95 | 0.160 |
Why?
|
| Narcotic Antagonists | 2 | 2011 | 184 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4848 | 0.150 |
Why?
|
| Lysophospholipids | 1 | 2019 | 209 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 201 | 0.150 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2017 | 24 | 0.150 |
Why?
|
| Aqueous Humor | 2 | 2008 | 51 | 0.150 |
Why?
|
| Sphingosine | 1 | 2019 | 315 | 0.150 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2011 | 95 | 0.150 |
Why?
|
| NAD | 1 | 2017 | 73 | 0.140 |
Why?
|
| Enzyme Activation | 3 | 2008 | 791 | 0.140 |
Why?
|
| Inflammation | 1 | 2022 | 1030 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2017 | 215 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 434 | 0.130 |
Why?
|
| Aged | 5 | 2020 | 14862 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 756 | 0.120 |
Why?
|
| Stilbamidines | 1 | 2014 | 13 | 0.120 |
Why?
|
| Neoplasms | 2 | 2017 | 1667 | 0.120 |
Why?
|
| Guanidines | 1 | 2014 | 32 | 0.120 |
Why?
|
| Sulfhydryl Compounds | 1 | 2014 | 73 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 1033 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 201 | 0.120 |
Why?
|
| Quinolines | 1 | 2014 | 48 | 0.120 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2013 | 3 | 0.120 |
Why?
|
| Sesquiterpenes | 1 | 2013 | 41 | 0.110 |
Why?
|
| Middle Aged | 5 | 2020 | 21147 | 0.110 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.110 |
Why?
|
| Cytoprotection | 1 | 2013 | 39 | 0.110 |
Why?
|
| Opioid Peptides | 1 | 2012 | 17 | 0.100 |
Why?
|
| Caspases | 1 | 2012 | 194 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 118 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 175 | 0.100 |
Why?
|
| Endothelin-1 | 2 | 2003 | 122 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2013 | 432 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2012 | 118 | 0.100 |
Why?
|
| Bradykinin | 2 | 2013 | 157 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 244 | 0.090 |
Why?
|
| Microglia | 1 | 2011 | 143 | 0.090 |
Why?
|
| Species Specificity | 2 | 2008 | 303 | 0.090 |
Why?
|
| Apoptosis | 1 | 2016 | 1641 | 0.090 |
Why?
|
| rho-Associated Kinases | 2 | 2007 | 32 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 84 | 0.090 |
Why?
|
| Ergolines | 1 | 2008 | 19 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 455 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 116 | 0.080 |
Why?
|
| Calcium Signaling | 2 | 2013 | 97 | 0.080 |
Why?
|
| Benzophenanthridines | 1 | 2008 | 5 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2008 | 63 | 0.080 |
Why?
|
| Time Factors | 3 | 2013 | 4655 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2007 | 216 | 0.080 |
Why?
|
| Macaca fascicularis | 3 | 2014 | 31 | 0.080 |
Why?
|
| Cricetulus | 3 | 2014 | 98 | 0.080 |
Why?
|
| CHO Cells | 3 | 2014 | 161 | 0.080 |
Why?
|
| Protein Transport | 1 | 2008 | 280 | 0.070 |
Why?
|
| Rats, Zucker | 1 | 2007 | 10 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 28 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 765 | 0.070 |
Why?
|
| Cattle | 2 | 2006 | 475 | 0.070 |
Why?
|
| Transfection | 1 | 2008 | 782 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2007 | 218 | 0.070 |
Why?
|
| Adenosine | 1 | 2006 | 165 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3259 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2006 | 371 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 1745 | 0.060 |
Why?
|
| Uridine Diphosphate | 1 | 2004 | 3 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 331 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Prostaglandins F | 1 | 2003 | 13 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 24 | 0.060 |
Why?
|
| Phosphatidylinositols | 1 | 2003 | 40 | 0.060 |
Why?
|
| Muscle Cells | 1 | 2003 | 30 | 0.060 |
Why?
|
| Phenylephrine | 1 | 2003 | 61 | 0.060 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2003 | 37 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2003 | 107 | 0.050 |
Why?
|
| Phospholipase C beta | 1 | 2002 | 5 | 0.050 |
Why?
|
| Desmin | 1 | 2002 | 13 | 0.050 |
Why?
|
| Inositol Phosphates | 1 | 2002 | 28 | 0.050 |
Why?
|
| Carbachol | 1 | 2002 | 34 | 0.050 |
Why?
|
| Myosins | 1 | 2002 | 34 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2002 | 164 | 0.050 |
Why?
|
| Dyneins | 1 | 2021 | 10 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2002 | 110 | 0.050 |
Why?
|
| Cricetinae | 2 | 2013 | 262 | 0.050 |
Why?
|
| Actins | 1 | 2002 | 249 | 0.050 |
Why?
|
| Bradykinin B2 Receptor Antagonists | 2 | 2013 | 13 | 0.050 |
Why?
|
| Rabbits | 2 | 2013 | 509 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1664 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 54 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1076 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 2 | 2013 | 223 | 0.040 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2019 | 63 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 947 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2017 | 20 | 0.040 |
Why?
|
| Glutamine | 1 | 2017 | 45 | 0.040 |
Why?
|
| Sirtuin 1 | 1 | 2017 | 47 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2017 | 101 | 0.040 |
Why?
|
| Dipeptides | 2 | 2008 | 89 | 0.040 |
Why?
|
| L-Selectin | 1 | 2016 | 28 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2017 | 116 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2016 | 30 | 0.030 |
Why?
|
| Necrosis | 1 | 2016 | 239 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1692 | 0.030 |
Why?
|
| Bromobenzenes | 1 | 2014 | 4 | 0.030 |
Why?
|
| Benzophenones | 1 | 2014 | 12 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 35 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 75 | 0.030 |
Why?
|
| Prostaglandins | 1 | 2013 | 65 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 73 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 397 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2012 | 18 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2012 | 35 | 0.030 |
Why?
|
| Adult | 2 | 2008 | 21403 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 672 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2012 | 91 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1851 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 489 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 1083 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1447 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 710 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 1200 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 455 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2010 | 74 | 0.020 |
Why?
|
| Histones | 1 | 2010 | 111 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 79 | 0.020 |
Why?
|
| Melanoma | 1 | 2012 | 335 | 0.020 |
Why?
|
| Thalidomide | 1 | 2008 | 24 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2008 | 111 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Cats | 1 | 2008 | 292 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2008 | 59 | 0.020 |
Why?
|
| Anterior Eye Segment | 1 | 2006 | 13 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 76 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 160 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2003 | 144 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2003 | 81 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 260 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 317 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 2083 | 0.010 |
Why?
|